“Supra-Omic”
Learn more about metabolomics and when to integrate with other omics
Why Metabolomics
Metabolomics is the systematic study of small-molecule metabolites (typically <1.5 kDa) and provides the most immediate and sensitive readout of cellular physiology. Metabolomics has been called “supra-omic” because it provides a real-time, functional snapshot of a cell’s physiological state, reflecting perturbations that occur downstream of genomics, transcriptomics, and proteomics. While genomics describes what could happen and proteomics describes what machinery is available, metabolomics provides a real-time snapshot of physiological and pathological states, describing what is happening right now in the biochemical network. Discordance between mRNA, protein, and metabolite levels is common due to translational control, enzyme kinetics, allosteric regulation, and substrate availability—factors that only metabolomics captures directly. In addition, metabolites are active regulators and not passive readouts, regulating genes, transcripts, and proteins by acting as signals and cofactors that influence transcription, RNA behavior, enzyme activity, post-translational modification, and protein stability. The upper figure shows an artistic visualization of the major omics layers, feedback loops and phenotype, annotated with the estimated number of molecular features for each omics. The Human Phenotype Ontology currently lists 18,000 phenotypic abnormalities.
Table 1 provides a simple overview of the major omics layers, focusing on their biological functions and temporal resolution:
| Omics Layer | Definition & Function | Time Scale of Change | Turnover Rate | Information Level |
|---|---|---|---|---|
| Genomics | The Blueprint: The complete set of DNA. Determines the organism’s potential and susceptibility. | Static: Largely unchanging throughout an individual’s lifetime (except for somatic mutations/cancer). | Stable | Potential: What can happen. |
| Epigenomics | The Switch: Chemical modifications (methylation, acetylation) to DNA/histones that turn genes on/off without changing the sequence. | Slow – Intermediate: Changes with age, lifestyle, and environmental exposure. Can act as a “cellular memory.” | Days to Years | Regulation: How the blueprint is accessed. |
| Transcriptomics | The Message: The set of RNA transcripts (mRNA). Reflects which genes are currently active/expressed. | Fast: Responds to stimuli (drugs, stress) rapidly. Captures the intent to produce proteins. | Minutes to Hours | Intent: What the cell is trying to do. |
| Proteomics | The Machinery: The set of expressed proteins. Executors of cellular function, signaling, and structure. | Intermediate: Slower than transcripts. Proteins are more stable and accumulate post-translationally. | Hours to Days | Execution: The functional machinery present. |
| Metabolomics | The Result (Phenotype): Small molecules (<1.5 kDa) like sugars, lipids, amino acids. The end-product of all cellular processes. | Instantaneous: Highly dynamic. Levels fluctuate in seconds to minutes in response to diet, exercise, or drugs. | Seconds to Minutes | State: What is actually happening right now. |
| Microbiomics | The Partner: The community of microorganisms (bacteria, viruses, fungi) living in/on the host (e.g., gut). | Mixed: Composition (DNA) is relatively stable (months/years), but Function (metabolic output) changes rapidly. | Hours (Function) to Months (Composition) | Ecosystem: The external functional capacity. |
Choose Metabolomics as the Primary Approach when
- The phenotype is biochemical or functional
Suspected alterations in energy metabolism, redox state, one‑carbon metabolism, lipid signaling, or amino‑acid pathways in disease or treatment response.
Biomarker discovery where the readout should be close to physiology (e.g. acylcarnitines for mitochondrial function, bile acids for liver–gut axis, SCFAs for gut barrier/immune tone). - Need for an integrative, end‑point view
To see the net result of genetics, epigenetics, transcription, translation, post‑translational regulation, microbiome activity, and environment on the biochemical state in one layer.
For stratification and subtyping where symptomatically similar patients may have distinct metabolic endophenotypes despite overlapping genomic findings. - The exposure is environmental, dietary, pharmacological, or microbiome‑mediated
Nutritional interventions, fasting/feeding cycles, exercise challenges, or xenobiotic exposure where the internal dose and downstream biochemical effects matter.
Drug metabolism, off‑target effects, and host–drug–microbiome interactions (e.g. bacterial biotransformation of drugs, altered bile acid pools). - The key feature is rapid dynamics
Time‑course studies of acute stress, circadian variation, or challenge tests (OGTT, clamp studies, meal tests) where metabolite trajectories capture functional capacity and regulation.
Perturbation experiments in cell/animal models where flux and intermediate accumulation are central readouts.
Multiomics
In multiomics designs, metabolomics frequently acts as the functional validation layer of upstream changes: a genetic variant or protein abundance shift may suggest pathway perturbation, but only metabolite measurements confirm that flux has actually changed. Combination of metabolomics with other layers (Table 2.) is transformative, because:
It separates signal from noise: Thousands of genes may be turned on, but only a few might actually alter cell metabolism. Metabolomics identifies which genetic changes are biologically relevant.
It captures the environment: Unlike the genome, which is static, the metabolome reacts to diet, drugs, and the microbiome. Combining them allows to investigate how the environment modifies genetic programming.
It enables precision medicine: It moves medicine from treating “risk factors” to treating the actual molecular dysfunction driving the disease.
| Combination with | Primary Insight | Key Mechanism | Major Applications |
|---|---|---|---|
| Microbiomics | Distinguishes whether a blood marker comes from human cells or gut bacteria. | Crosstalk:Microbial metabolites (like SCFAs) act as signaling molecules that regulate human genes. | • Gut-Brain Axis (Alzheimer’s) • Liver Disease (MASLD) • Diabetes |
| Proteomics | Validates function. High protein levels don’t always mean high activity; metabolites confirm the enzyme is working. | PTMs: Metabolites trigger “switches” (like phosphorylation) that turn proteins on/off. | • Disease Subtyping (e.g., Alzheimer’s) • Heart Failure prediction • Functional Biology |
| Epigenomics | Explains how environment/diet physically alters DNA regulation. | Cofactors: Epigenetic enzymes need fuel (metabolites like Acetyl-CoA) to modify DNA. | • Cancer (Oncometabolites) • Aging mechanisms • Dietary impact on genes |
| Genomics | Bridges the gap between genetic risk and actual disease. | Intermediate Phenotypes: Traces the path from Gene to Metabolite to Disease. | • Precision Medicine • Prostate Cancer therapy • Validating genetic variants |
Integration of microbiome and metabolome data is emerging as a powerful approach to dissect host–microbe interactions in metabolic liver disease and other complex conditions. Microbiota-derived metabolites such as
- Short-Chain Fatty Acids (SCFAs): Produced by microbial fermentation of dietary fibers, SCFAs (acetate, propionate, butyrate) regulate gut barrier integrity, immune responses, and energy metabolism. Butyrate, in particular, inhibits histone deacetylases (HDACs), linking microbial metabolism to host epigenetic regulation,
- Bile Acids: Primary bile acids synthesized by the liver are converted to secondary bile acids by gut bacteria. These metabolites act as signaling molecules via nuclear receptors (e.g., FXR, TGR5), influencing lipid and glucose homeostasis, and inflammation,
- Indoles and Tryptophan Metabolites: Microbial metabolism of tryptophan produces indoles, which activate host receptors (e.g., AhR, PXR), modulating gene expression, immunity, and gut barrier function,
modulate host immunity, gene expression, and systemic metabolism. Conversely, host-controlled metabolic outputs, particularly bile acid synthesis and immune signaling pathways, help shape microbial community composition and functional potential.
